• James B. Bussel
  • Mariana P. Pinheiro
Part of the Cancer Treatment and Research book series (CTAR, volume 157)


The current concepts and the management of ITP have significantly changed in the past decade. Decreased use of cytotoxic therapy and the introduction of new selective modalities of drug such as TPO-r mimetics are the landmarks of this change. Discovered in the middle of last decade, followed by experiments in mice and then approved in humans, Eltrombopag is the first TPO-r mimetic available. It has been used and validated in several clinical studies in different etiologies of thrombocytopenia, including primary ITP (chronic Immune ThrombocytoPenia) and secondary ITP, due to hepatitis C and more recently in bone marrow failure as myelodysplastic syndromes. Good tolerability and low side effects are the strengths of this drug, contrasted with issues regarding administration (it must be taken every day apart from specific meals containing high levels of calcium, which leads to problems with compliance). We review the first clinical studies with this agent, emphasizing the significant findings.


Platelet Count Bone Marrow Fibrosis Increase Platelet Count Baseline Platelet Count Median Platelet Count 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Erickson-Miller C, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009;27:424–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Duffy KJ, Erickson-Miller CL. The discovery of eltrombopag, an orally bioavailable TpoR agonist. In: Metcalf BW, Dillon S, editors. Target validation in drug discovery. Burlington, MA: Academic Press; 2007. pp. 241–254.Google Scholar
  3. 3.
    Jenkins JM, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109:4739–41.CrossRefPubMedGoogle Scholar
  4. 4.
    Bussel JB, et al. Eltrombopag for the treatment of Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237–47.CrossRefPubMedGoogle Scholar
  5. 5.
    Bussel JB, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomized, double-blind, placebo-controlled trial. Lancet. 2009;373:641–8.CrossRefPubMedGoogle Scholar
  6. 6.
    McHutchinson JG, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227–36.CrossRefGoogle Scholar
  7. 7.
    Cheng G, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomized, phase 3 study. Lancet, 2010, in press.Google Scholar
  8. 8.
    EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP) – EXTEND STUDY.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Pediatric Hematology–Oncology, Department of Pediatrics in Obstetrics and Gynecology and in MedicineWeill Cornell Medical College, New York Presbyterian Hospital, Weill Cornell Medical CenterNew YorkUSA
  2. 2.Division of Pediatric Hematology–OncologyWeill Cornell Medical Center, Weill Cornell Medical College, New York Presbyterian HospitalNew YorkUSA

Personalised recommendations